Su Judy Y, Vo Anhkiet C
Department of Anesthesiology, University of Washington, Box 356540, Seattle, WA 98195, USA.
Eur J Pharmacol. 2007 Mar 22;559(2-3):189-95. doi: 10.1016/j.ejphar.2006.12.016. Epub 2007 Jan 16.
The receptor(s) used by cannabinoids to relax vascular smooth muscle is unknown. Here, we investigated the effects of 2-arachidonylglyceryl ether (2-AG ether), a metabolically stable endocannabinoid, and abnormal cannabidiol (abn-CBD) on relaxation of permeabilized pulmonary arterial strips monitored with force, and on extracellular signal-regulated mitogen-activated protein kinases (ERK1/2) phosphorylation in permeabilized vascular smooth muscle cells using immunoblotting. We found that 2-AG ether and abn-CBD caused relaxation and increased phosphorylation of ERK1/2. 2-AG ether effects were completely abolished by N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), and N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A), and partially blocked by (-)-1.3-dimethoxy-2-(3-3,4-trans-p-menthadien-(1,8)-yl)-orcinol (O-1918). In contrast, abn-CBD effects were completely abolished by O-1918, and only partially blocked by AM251, and SR141716A. Both 2-AG ether and abn-CBD effects were partially blocked by pertussis toxin, an inhibitor of Gi/o proteins. PD98059, an inhibitor of mitogen activated protein kinase kinase (MEK), completely abolished the relaxation, but only partially blocked the increased phosphorylation of ERK1/2 by 2-AG ether. In contrast, abn-CBD-induced relaxation was partially blocked and the increased phosphorylation of ERK1/2 was abolished by PD98059. These findings suggest that 2-AG ether and abn-CBD-induced vascular smooth muscle relaxation are mediated by the cannabinoid CB1 receptor, and the abn-CBD receptor, respectively, and are modulated by cross-talk between the receptors. These responses occur mainly by coupling to pertussis toxin sensitive G proteins, but also, in part independent of these G proteins, which have been classically thought to initiate MEK/ERK1/2 signaling to relax vascular smooth muscle.
大麻素用于舒张血管平滑肌的受体尚不清楚。在此,我们研究了代谢稳定的内源性大麻素2-花生四烯酸甘油醚(2-AG醚)和异常大麻二酚(abn-CBD)对用力监测的透化肺动脉条舒张的影响,以及使用免疫印迹法对透化血管平滑肌细胞中细胞外信号调节丝裂原活化蛋白激酶(ERK1/2)磷酸化的影响。我们发现2-AG醚和abn-CBD可引起ERK1/2的舒张和磷酸化增加。N-(哌啶-1-基)-5-(4-碘苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酰胺(AM251)和N-(哌啶-1-基)-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酰胺(SR141716A)可完全消除2-AG醚的作用,(-)-1.3-二甲氧基-2-(3-3,4-反式-薄荷二烯-(1,8)-基)-苔黑素(O-1918)可部分阻断其作用。相比之下,O-1918可完全消除abn-CBD的作用,AM251和SR141716A仅能部分阻断其作用。百日咳毒素(一种Gi/o蛋白抑制剂)可部分阻断2-AG醚和abn-CBD的作用。丝裂原活化蛋白激酶激酶(MEK)抑制剂PD98059可完全消除舒张作用,但仅部分阻断2-AG醚引起的ERK1/2磷酸化增加。相比之下,PD98059可部分阻断abn-CBD诱导的舒张,并消除其引起的ERK1/2磷酸化增加。这些发现表明,2-AG醚和abn-CBD诱导的血管平滑肌舒张分别由大麻素CB1受体和abn-CBD受体介导,并受受体间相互作用的调节。这些反应主要通过与百日咳毒素敏感的G蛋白偶联发生,但也部分独立于这些传统上认为可启动MEK/ERK1/2信号以舒张血管平滑肌的G蛋白。